RAB5B and cancer: This analysis was conducted using data from the Cancer Therapeutics Response Portal (CTRP) and the Genomics of Drug Sensitivity in Cancer (GDSC) datasets, which provided comprehensive information on drug responses and gene expression profiles across a wide range of cancer cell lines.On the contrary, the expression of RAB5B was negatively correlated with the response to numerous cancer medications such as PX-12, PRIMA-1, PL-DI, panobinostat, navitoclax, CCT036477 and apicidin.